Trending: Halozyme Drops Bid for Evotec

Dow Jones

2024-11-23

1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)

(END) Dow Jones Newswires

November 22, 2024 13:50 ET (18:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2485909142"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485909142\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485909142?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-23 02:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485909142","market":"other","top_or_hot":-1,"title":"Trending: Halozyme Drops Bid for Evotec","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones &amp; Co. owns Factiva. (matthew.walker@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 13:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Halozyme Drops Bid for Evotec</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Halozyme Drops Bid for Evotec\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-23 02:50</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones &amp; Co. owns Factiva. (matthew.walker@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 13:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485909142","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485909142","pubTimestamp":1732301400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros . Dow Jones & Co. owns Factiva. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HALO":"奥洛兹美医疗","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"趋势：Halozyme放弃对Evotec的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 13:50 ET (18:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}